Foamix develops innovative topical foam products for dermatology and gynecology.
The company partners with global pharmaceutical companies to create patent protected topical products with a variety of drugs including new chemical entities.
Advantages of Foamix foam products include increased permeability and drug delivery, convenient form of presentation preferred by users, and enhanced efficacy in clinical studies.
For Acne, Rosacea and Skin Infections.
Acne Phase II reveals exceptional clinical results:
- Over 70% decrease in inflammatory lesions after 6 weeks
- 70% decrease in non–inflammatory lesions
- Highly preferred by patients over alternative drugs
- No drug related systemic side effects
Foamix Announces the Issuance of Five Additional US Patents
Covers Multiple Technology Platforms and Minocycline Foam
Foamix, Ltd., to Present at the 34th Annual Cowen & Company Health Care Conference -- Successful Phase 2 for First Ever Topical Minocycline for Acne and ImpetigoRead more...